Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
T-cell composition before apheresis and CAR-T (CD4/CD8 CAR-T ratio >0.09, more non-activated/-cytolytic CAR-T) and endogenous T-cell phenotypes (increased % PD1+ cytotoxic T cell and ICOS-TIGIT+ Treg) post-infusion link w/ PFS.”
Title: Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma
Authors: Bruno Paiva, Irene Manrique, Ethan Thompson, Timothy B. Campbell, Camila Guerrero, Nathan Martin, Larry D. Anderson Jr., Jesús G. Berdeja, Sagar Lonial, Noopur S. Raje, Yi Lin, Philippe Moreau, Jesús F. San-Miguel, Nikhil C. Munshi, Shari Kaiser
You can read the Full Article on HemaSphere. 
You can find other articles featuring Robert Orlowski on OncoDaily.
